Sulfinpyrazone
From Infogalactic: the planetary knowledge core
File:Sulfinpyrazone.svg | |
Systematic (IUPAC) name | |
---|---|
1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
|
|
Clinical data | |
Trade names | Apo-sulfinpyrazone |
AHFS/Drugs.com | monograph |
MedlinePlus | a682339 |
Routes of administration |
oral intravenous |
Pharmacokinetic data | |
Protein binding | 98–99% |
Metabolism | hepatic |
Excretion | renal |
Identifiers | |
CAS Number | 57-96-5 |
ATC code | M04AB02 (WHO) |
PubChem | CID: 5342 |
IUPHAR/BPS | 5826 |
DrugBank | DB01138 |
ChemSpider | 5149 |
UNII | V6OFU47K3W |
KEGG | D00449 |
ChEBI | CHEBI:9342 |
ChEMBL | CHEMBL832 |
Chemical data | |
Formula | C23H20N2O3S |
Molecular mass | 404.48 g/mol |
|
|
|
|
(verify) |
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Contraindications
Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).[1]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>